Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102) (International Journal of Clinical Oncology, (2016), 21, 4, (705-712), 10.1007/s10147-015-0943-z)